开放与微创子宫肌瘤剔除术中围手术期非激素药物减少出血的系统综述与网状Meta分析
该研究纳入26项随机对照试验(N=1627),通过网络Meta分析评估缩宫素、去氨加压素、氨甲环酸等药物在子宫肌瘤剔除术中减少出血的效果。微创组中缩宫素减少出血排名第一;开放组中垂体后叶素联合米索前列醇排名第一,但证据质量均低。
要点
- 微创子宫肌瘤剔除术中缩宫素减少出血排名第一,其次为鸟氨酸加压素。
- 开放子宫肌瘤剔除术中垂体后叶素联合米索前列醇减少出血排名第一(P=.97)。
- 支持上述药物减少出血和输血需求的证据质量均为低。
核心结论
- 有低质量证据支持子宫收缩剂(尤其是缩宫素)和外周血管收缩剂是微创子宫肌瘤剔除术中减少出血和输血需求的有效选择。
- 缩宫素是微创子宫肌瘤剔除术中最有效的干预措施。
- 对于开放子宫肌瘤剔除术,需要子宫收缩剂与外周血管收缩剂联合使用才能有效减少出血。
研究设计与样本
- 系统综述与随机对照试验(RCT)的网状Meta分析,纳入26项RCT(N=1627)。
- 微创手术亚组纳入9项RCT(474例患者),开放手术亚组纳入17项RCT(1153例患者)。
主要发现
- 微创手术中,缩宫素(MD -175.5 mL,95%CI -30.1.07至-49.93)、鸟氨酸加压素(MD -149.6 mL,95%CI -178.22至-120.98)、米索前列醇、布比卡因联合肾上腺素及垂体后叶素均有效减少出血,但证据质量低。
- 微创手术排名:缩宫素减少出血排名第一,鸟氨酸加压素第二。
- 开放手术中,垂体后叶素联合米索前列醇(MD -652.97 mL,95%CI -1113.69至-174.26)、缩宫素、氨甲环酸及米索前列醇均有效,但证据质量低。
- 开放手术中垂体后叶素联合米索前列醇减少出血排名第一(P=.97)。
关键数值与推荐
- 微创手术:缩宫素MD -175.5 mL(95%CI -30.1.07至-49.93),证据质量低。
- 微创手术:鸟氨酸加压素MD -149.6 mL(95%CI -178.22至-120.98),证据质量低。
- 开放手术:垂体后叶素联合米索前列醇MD -652.97 mL(95%CI -1113.69至-174.26),证据质量低。
- 开放手术:垂体后叶素联合米索前列醇减少出血排名第一(P=.97)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 微创手术和开放手术亚组中有效干预措施的证据质量均为低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To synthesize evidence on the most effective pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy. DESIGN: Systematic review and network meta-analysis of randomized controlled trials (RCTs). SETTING: Not applicable. PATIENTS: Trials assessing efficacy of pharmacological interventions during different types of myomectomy. INTERVENTIONS: Misoprostol, oxytocin, vasopressin, tranexamic acid (TXA), epinephrine, or ascorbic acid. MAIN OUTCOME MEASURES: Intraoperative blood loss and need for blood transfusion. RESULTS: The present review included 26 randomized control trials (RCTs) (N = 1627). For minimally invasive procedures (9 RCTs; 474 patients), network meta-analysis showed that oxytocin (mean difference [MD] -175.5 mL, 95% confidence interval [CI] -30.1.07, -49.93), ornipressin (MD -149.6 mL, 95% CI - 178.22, -120.98), misoprostol, bupivacaine plus epinephrine, and vasopressin were effective in reducing myomectomy blood loss, but the evidence is of low quality. Ranking score of treatments included in subgroup analysis of minimally invasive myomectomy showed that oxytocin ranked first in reducing blood loss, followed by ornipressin. For open myomectomy (17 RCTs; 1,153 patients), network meta-analysis showed that vasopressin plus misoprostol (MD -652.97 mL, 95% CI - 1113.69, -174.26), oxytocin, TXA, and misoprostol were effective; however, the evidence is of low quality. Vasopressin plus misoprostol ranked first in reducing blood loss during open myomectomy (P = .97). CONCLUSION: There is low-quality evidence to support uterotonics, especially oxytocin, and peripheral vasoconstrictors as effective options in reducing blood loss and need for blood transfusion during minimally invasive myomectomy. Oxytocin is the most effective intervention in minimally invasive myomectomy. For open myomectomy, a combination of uterotonics and peripheral vasoconstrictors is needed to effectively reduce blood loss.
引用
- Samy A, Raslan AN, Talaat B, et al. Perioperative nonhormonal pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy: a systematic review and network meta-analysis. Fertil Steril. 2019. PMID: 31753311. doi:10.1016/j.fertnstert.2019.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。